PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32202904-10 2020 Results showed that the expression of p-p53, p53, Bax and PUMA was upregulated after CBL0137 administration. CBLC137 85-92 tumor protein p53 Homo sapiens 40-43 32202904-10 2020 Results showed that the expression of p-p53, p53, Bax and PUMA was upregulated after CBL0137 administration. CBLC137 85-92 tumor protein p53 Homo sapiens 45-48 35323988-2 2022 The curaxin CBL0137 has demonstrated promising antitumour activities in multiple cancers such as glioblastoma, acting through p53 activation, NF-kappaB inhibition and chromatin remodelling. CBLC137 12-19 tumor protein p53 Homo sapiens 126-129 35323988-3 2022 In the present study, it was revealed using Annexin-V/7-AAD apoptosis assays that CBL0137 has efficacy across several human acute leukaemia cell lines with wild-type TP53, but sensitivity is reduced in TP53-mutated subtypes. CBLC137 82-89 tumor protein p53 Homo sapiens 166-170 35323988-3 2022 In the present study, it was revealed using Annexin-V/7-AAD apoptosis assays that CBL0137 has efficacy across several human acute leukaemia cell lines with wild-type TP53, but sensitivity is reduced in TP53-mutated subtypes. CBLC137 82-89 tumor protein p53 Homo sapiens 202-206 35323988-4 2022 A heterozygous TP53 loss-of-function mutation in the KMT2A-AFF1 human RS4;11 cell line was generated, and it was demonstrated that heterozygous TP53 loss-of-function is sufficient to cause a significant reduction in CBL0137 sensitivity. CBLC137 216-223 tumor protein p53 Homo sapiens 144-148 35323988-5 2022 To the best of our knowledge, this is the first evidence to suggest a clinically significant role for functional p53 in the efficacy of CBL0137 in acute leukaemia. CBLC137 136-143 tumor protein p53 Homo sapiens 113-116 35323988-6 2022 Future CBL0137 clinical trials should include TP53 mutation screening, to establish the clinical relevance of TP53 mutations in CBL0137 efficacy. CBLC137 128-135 tumor protein p53 Homo sapiens 110-114 33852836-3 2021 We show that CBL0137 displays profound cytotoxic activity against a panel of patient-derived DIPG cultures by restoring tumor suppressor TP53 and Rb activity. CBLC137 13-20 tumor protein p53 Homo sapiens 137-141 27370399-3 2017 One such clinical-stage drug candidate, CBL0137, is a curaxin, small molecules which simultaneously downregulate nuclear factor-kappaB (NF-kB) and activate p53 by inactivating the chromatin remodeling complex, Facilitates Chromatin Transcription (FACT). CBLC137 40-47 tumor protein p53 Homo sapiens 156-159 27370399-8 2017 CBL0137 induced loss of chromatin-unbound FACT, activated p53, inhibited NF-kB-dependent transcription, and was toxic to GBM cells. CBLC137 0-7 tumor protein p53 Homo sapiens 58-61 35323988-0 2022 TP53 loss-of-function mutations reduce sensitivity of acute leukaemia to the curaxin CBL0137. CBLC137 85-92 tumor protein p53 Homo sapiens 0-4